Sleep disorders: Patients underwent polysomnography before the start of GH treatment at a median age of 8.5 months (range 5.1–10.7 months) in the OT-exposed group (n = 13) versus 12.6 months (range 7.3–26) in the non-exposed group (n = 12). Here, GH1 is linked to sleep disorder.